NLS Pharmaceutics AG (NLSP) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    NLS Pharmaceutics AG

    NASDAQ: NLSP · Real-Time Price · USD
    2.00
    -0.12 (-5.66%)
    At close: Oct 03, 2025, 3:59 PM
    1.99
    -0.25%
    Pre-market: Oct 06, 2025, 08:48 AM EDT

    NLS Pharmaceutics Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -1.98M -12.17M -16.5M -11.95M
    Depreciation & Amortization
    		 3.32K 11.41K 11.41K 10.05K
    Stock-Based Compensation
    		 125.64K 164.91K 22.73K n/a
    Other Working Capital
    		 195.74K -8.54K 990.55K -875.26K
    Other Non-Cash Items
    		 -2.49M 59.53K 341.94K 166.51K
    Deferred Income Tax
    		 n/a n/a 613.42K n/a
    Change in Working Capital
    		 77.69K 2.25M 1.63M -3.17M
    Operating Cash Flow
    		 -4.27M -9.68M -13.88M -14.94M
    Capital Expenditures
    		 -3.92K -4 n/a -39.56K
    Cash Acquisitions
    		 n/a n/a n/a n/a
    Purchase of Investments
    		 n/a n/a n/a n/a
    Sales Maturities Of Investments
    		 n/a n/a n/a n/a
    Other Investing Acitivies
    		 n/a 4.00 -3.51M n/a
    Investing Cash Flow
    		 -3.92K n/a -3.51M -39.56K
    Debt Repayment
    		 n/a 1.63M 825.84K -2.1M
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 -213.21K n/a 7.35M 7.89M
    Financial Cash Flow
    		 5.04M 1.63M 17.4M 20.34M
    Net Cash Flow
    		 767.72K -8.05M 3.52M 5.34M
    Free Cash Flow
    		 -4.27M -9.68M -13.88M -14.98M

    Add to Watchlist